Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGM0504 Phase 2a in Type 2 Diabetes
NCT06974825Phase 2Completed
- Sponsor
- BrightGene Bio-Medical Technology
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BGM0504 in type 2 diabetes mellitus (T2DM), sponsored by BrightGene Bio-Medical Technology. Started Aug 2023; status: completed.
02
Drugs
BGM0504
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06974825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06974825.